Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ayten Yazici is active.

Publication


Featured researches published by Ayten Yazici.


Nature Genetics | 2013

Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease

Travis Hughes; Patrick Coit; Adam Adler; Vuslat Yilmaz; Kenan Aksu; Nurşen Düzgün; Gokhan Keser; Ayse Cefle; Ayten Yazici; Andac Ergen; Erkan Alpsoy; Carlo Salvarani; Bruno Casali; Ina Kötter; Javier Gutierrez-Achury; Cisca Wijmenga; Güher Saruhan-Direskeneli; Amr H. Sawalha

Behçets disease is an inflammatory disease characterized by recurrent oral and genital ulcers and significant organ involvement. Localizing the genetic association between HLA-B*51 and Behçets disease and exploring additional susceptibility loci in the human leukocyte antigen (HLA) region are complicated by the strong linkage disequilibrium in this region. We genotyped 8,572 variants in the extended HLA locus and carried out imputation and meta-analysis of 24,834 variants in 2 independent Behçets disease cohorts from 2 ancestry groups. Genotyped SNPs were used to infer classical HLA alleles in the HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1 and HLA-DRB1 loci. Our data suggest that the robust HLA-B*51 association in Behçets disease is explained by a variant located between the HLA-B and MICA genes (rs116799036: odds ratio (OR) = 3.88, P = 9.42 × 10−50). Three additional independent genetic associations within PSORS1C1 (rs12525170: OR = 3.01, P = 3.01 × 10−26), upstream of HLA-F-AS1 (rs114854070: OR = 1.95, P = 7.84 × 10−14) and with HLA-Cw*1602 (OR = 5.38, P = 6.07 × 10−18) were also identified and replicated.


Rheumatology International | 2010

The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

E. Örge; Ayse Cefle; Ayten Yazici; N. Gürel-Polat; Sadettin Hulagu

Chronic hepatitis C virus (HCV) has extrahepatic autoimmune properties and a variety of autoantibodies were found in patients with HCV. Patients with HCV infection may have rheumatic symptoms and signs, and 50–70% of the cases may contain rheumatoid factor (RF). The increased prevalence of RF in patients with HCV infection diminishes the diagnostic specificity of serum RF for rheumatoid arthritis (RA) in patients with HCV. Therefore, the presence of RF mostly does not help in distinguishing between RA and HCV-associated rheumatic symptoms. In this study, we studied whether cyclic citrullinated peptide (CCP) antibody, a highly specific biomarker for RA in the general population, was useful for the diagnosis of RA in nonarthritic patients with HCV (hepatitis C virus). Blood samples from 39 patients with chronic HCV infection, 87 normal sera from volunteer blood donors and 108 blood samples from patients with rheumatoid arthritis, from the rheumatology clinic, were taken. RF was measured using the Dade-Behring nephelometer and antibodies to CCP were measured with ELISA. According to statistical analysis, the sensitivity, specificity and positive predictive value of the anti-CCP test was superior to the RF test. Cyclic citrullinated peptide antibody is a more useful test than RF among patients with chronic HCV infection without arthritis.


Arthritis & Rheumatism | 2015

Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study

Paul Renauer; Güher Saruhan-Direskeneli; Patrick Coit; Adam Adler; Kenan Aksu; Gokhan Keser; Fatma Alibaz-Oner; Sibel Zehra Aydin; Sevil Kamali; Murat Inanc; Simon Carette; David Cuthbertson; Gary S. Hoffman; Servet Akar; Fatos Onen; Nurullah Akkoc; Nader Khalidi; Curry L. Koening; Omer Karadag; Sedat Kiraz; Carol A. Langford; Kathleen Maksimowicz-McKinnon; Carol A. McAlear; Zeynep Ozbalkan; Aşkın Ateş; Yasar Karaaslan; Nurşen Düzgün; Paul A. Monach; Huseyin T. E. Ozer; Eren Erken

Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome‐wide association analysis of Takayasu arteritis.


The Journal of Rheumatology | 2016

Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence

Bunyamin Kisacik; Omer Nuri Pamuk; Ahmet Mesut Onat; Sait Burak Erer; Gulen Hatemi; Yesim Ozguler; Yavuz Pehlivan; L. Kilic; I. Ertenli; Meryem Can; Haner Direskeneli; Gokhan Keser; Fahrettin Oksel; Ediz Dalkilic; Sedat Yilmaz; Salih Pay; Ayse Balkarli; Veli Cobankara; Gozde Yildirim Cetin; Mehmet Sayarlioglu; Ayse Cefle; Ayten Yazici; Ali Berkant Avci; Ender Terzioglu; Suleyman Ozbek; Servet Akar; Ahmet Gül

Objective. Screening strategies for latent tuberculosis (TB) before starting tumor necrosis factor (TNF)-α inhibitors have decreased the prevalence of TB among patients who are treated with these agents. However, despite vigilant screening, TB continues to be an important problem, especially in parts of the world with a high background TB prevalence. The aim of this study was to determine the factors related to TB among a large multicenter cohort of patients who were treated with anti-TNF. Methods. Fifteen rheumatology centers participated in this study. Among the 10,434 patients who were treated with anti-TNF between September 2002 and September 2012, 73 (0.69%) had developed TB. We described the demographic features and disease characteristics of these 73 patients and compared them to 7695 patients who were treated with anti-TNF, did not develop TB, and had complete data available. Results. Among the 73 patients diagnosed with TB (39 men, 34 women, mean age 43.6 ± 13 yrs), the most frequent diagnoses were ankylosing spondylitis (n = 38) and rheumatoid arthritis (n = 25). More than half of the patients had extrapulmonary TB (39/73, 53%). Six patients died (8.2%). In the logistic regression model, types of anti-TNF drugs [infliximab (IFX), OR 3.4, 95% CI 1.88–6.10, p = 0.001] and insufficient and irregular isoniazid use (< 9 mos; OR 3.15, 95% CI 1.43–6.9, p = 0.004) were independent predictors of TB development. Conclusion. Our results suggest that TB is an important complication of anti-TNF therapies in Turkey. TB chemoprophylaxis less than 9 months and the use of IFX therapy were independent risk factors for TB development.


International Journal of Rheumatic Diseases | 2014

Diagnostic dilemma of paraneoplastic arthritis: case series.

Bunyamin Kisacik; Ahmet Mesut Onat; Timuçin Kaşifoğlu; Yavuz Pehlivan; Omer Nuri Pamuk; Ediz Dalkilic; Salim Dönmez; Sule Yasar Bilge; Sedat Yilmaz; Hakan Erdem; R. Mercan; Mehmet Akif Öztürk; Cemal Bes; Mehmet Soy; Sukran Erten; Veli Cobankara; Soner Senel; Fatma Alibaz Öner; Sema Yilmaz; Ayten Yazici; Hakan Emmungil; Kenan Aksu; Seval Kul; Gözde Yıldırım Çetin; Mehmet Sayarlioglu

Paraneoplastic arthritis (PA) may mimic rheumatic diseases. While presenting the demographic and laboratory features of the patients diagnosed with PA, this study also aims to provide possible appropriate tools to differentiate the PA cases from early rheumatoid arthritis (ERA).


The Journal of Rheumatology | 2016

Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study

G. Ozen; N. Inanc; Unal Au; Bas S; G. Kimyon; Kisacik B; Ahmet Mesut Onat; Murat S; Keskin H; Can M; Mengi A; Cakir N; Balkarli A; Cobankara; Yilmaz N; Ayten Yazici; Dogru A; Sahin M; Sahin A; Gok K; Senel S; Omer Nuri Pamuk; Sema Yilmaz; Bayindir O; Kenan Aksu; Cagatay Y; Akyol L; Mehmet Sayarlioglu; Yildirim-Cetin G; Yasar-Bilge S

Objective. To assess the performance of the new 2012 provisional European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) clinical classification criteria in discriminating PMR from other mimicking conditions compared with the previous 5 diagnostic criteria in a multicenter prospective study. Methods. Patients older than 50 years, presenting with new-onset bilateral shoulder pain with elevated acute-phase reactants (APR), were assessed for the fulfillment of the new and old classification/diagnostic criteria sets for PMR. At the end of the 1-year followup, 133 patients were diagnosed with PMR (expert opinion) and 142 with non-PMR conditions [69 rheumatoid arthritis (RA)]. Discriminating capacity, sensitivity, and specificity of the criteria sets were estimated. Results. Discriminating capacity of the new clinical criteria for PMR from non-PMR conditions and RA as estimated by area under the curve (AUC) were good with AUC of 0.736 and 0.781, respectively. The new criteria had a sensitivity of 89.5% and a specificity of 57.7% when tested against all non-PMR cases. When tested against all RA, seropositive RA, seronegative RA, and non-RA control patients, specificity changed to 66.7%, 100%, 20.7%, and 49.3%, respectively. Except for the Bird criteria, the 4 previous criteria had lower sensitivity and higher specificity (ranging from 83%–93%) compared with the new clinical criteria in discriminating PMR from all other controls. Conclusion. The new 2012 EULAR/ACR clinical classification criteria for PMR is highly sensitive; however, its ability to discriminate PMR from other inflammatory/noninflammatory shoulder conditions, especially from seronegative RA, is not adequate. Imaging and other modifications such as cutoff values for APR might increase the specificity of the criteria.


Journal of Autoimmunity | 2016

Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort.

Umut Kalyoncu; Dilek Solmaz; Hakan Emmungil; Ayten Yazici; Timuçin Kaşifoğlu; G. Kimyon; Ayse Balkarli; Cemal Bes; Mustafa Ozmen; Fatma Alibaz-Oner; Sukran Erten; Yonca Çağatay; Gözde Yıldırım Çetin; Sedat Yilmaz; Fatih Yildiz; Omer Nuri Pamuk; Orhan Küçükşahin; L. Kilic; Veli Yazisiz; Omer Karadag; Süleyman Serdar Koca; Mutlu Hayran; Servet Akar; Kenan Aksu; Nurullah Akkoc; Gokhan Keser; E. Gonullu; Bunyamin Kisacik; Ahmet Mesut Onat; Mehmet Soy

BACKGROUND Adult-onset Stills disease (AOSD) is a rare condition, and treatment choices are frequently dependent on expert opinions. The objectives of the present study were to assess treatment modalities, disease course, and the factors influencing the outcome of patients with AOSD. METHODS A multicenter study was used to reach sufficient patient numbers. The diagnosis of AOSD was based on the Yamaguchi criteria. The data collected included patient age, gender, age at the time of diagnosis, delay time for the diagnosis, typical AOSD rash, arthralgia, arthritis, myalgia, sore throat, lymphadenopathy, hepatomegaly, splenomegaly, pleuritis, pericarditis, and other rare findings. The laboratory findings of the patients were also recorded. The drugs initiated after the establishment of a diagnosis and the induction of remission with the first treatment was recorded. Disease patterns and related factors were also investigated. A multivariate analysis was performed to assess the factors related to remission. RESULTS The initial data of 356 patients (210 females; 59%) from 19 centers were evaluated. The median age at onset was 32 (16-88) years, and the median follow-up time was 22 months (0-180). Fever (95.8%), arthralgia (94.9%), typical AOSD rash (66.9%), arthritis (64.6%), sore throat (63.5%), and myalgia (52.8%) were the most frequent clinical features. It was found that 254 of the 306 patients (83.0%) displayed remission with the initial treatment, including corticosteroids plus methotrexate with or without other disease-modifying antirheumatic drugs. The multivariate analysis revealed that the male sex, delayed diagnosis of more than 6 months, failure to achieve remission with initial treatment, and arthritis involving wrist/elbow joints were related to the chronic disease course. CONCLUSION Induction of remission with initial treatment was achieved in the majority of AOSD patients. Failure to achieve remission with initial treatment as well as a delayed diagnosis implicated a chronic disease course in AOSD.


Arthritis & Rheumatism | 2015

Genome-wide association study identifies susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu’s arteritis

Paul Renauer; Güher Saruhan-Direskeneli; Patrick Coit; Adam S. Adler; Kenan Aksu; Gokhan Keser; Fatma Alibaz-Oner; Sibel Zehra Aydin; Sevil Kamali; Murat Inanc; Simon Carette; David Cuthbertson; Gary S. Hoffman; Servet Akar; Fatos Onen; Nurullah Akkoc; Nader Khalidi; Curry L. Koening; Omer Karadag; Sedat Kiraz; Carol A. Langford; Kathleen Maksimowicz-McKinnon; Carol A. McAlear; Zeynep Ozbalkan; Aşkın Ateş; Yasar Karaaslan; Nurşen Düzgün; Paul A. Monach; Huseyin T. E. Ozer; Eren Erken

Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome‐wide association analysis of Takayasu arteritis.


Joint Bone Spine | 2014

Rosacea associated with etanercept

Ayten Yazici; Aysun Sikar Akturk; Ayse Cefle; Dilek Bayramgürler; Kursat Yildiz

Joint Bone Spine - In Press.Proof corrected by the author Available online since samedi 7 decembre 2013


The International Journal of Lower Extremity Wounds | 2018

A Rare Cause of Leg Ulcer: Calcinosis Cutis as a Part of CREST Syndrome

Evren Odyakmaz Demirsoy; Cansu Çatal; Ayten Yazici; Dilek Bayramgürler

Leg ulcers are not a disease themselves, they are a symptom of a disease. To manage them properly, finding the correct diagnosis of the disease is mandatory. Our case is a model to underline that leg ulcers are a significant burden for the patient, because leg ulcer got ahead of the patient’s other serious complaints such as Raynaud’s phenomenon or sclerodactyly. Furthermore, our patient is also a model, and an attentive clinical evaluation is inevitable to find the correct diagnosis. We present our case aiming to underline the significance of full dermatologic examination in each ulceration to discover underlying disease.

Collaboration


Dive into the Ayten Yazici's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Timuçin Kaşifoğlu

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge